AstraZeneca

AstraZeneca moved to bolster the company’s COVID-19 portfolio of antibodies on May 17 with a $157 million licensing deal for experimental therapies developed by newly launched biotech RQ Bio.

Cullinan Oncology and Taiho Pharmaceutical announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize a non-small cell lung cancer (NSCLC) drug.

BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.

Five months after launching, Acrivon Therapeutics secured $100 million in an oversubscribed Series B financing round to support the clinical development of a cancer asset licensed from Eli Lilly and advance the company’s precision proteomics platform.

Pfizer

Cambridge, Mass.-based Voyager Therapeutics entered a deal allowing Pfizer to exercise options to license novel capsids for gene therapies.

Seagen (formerly known as Seattle Genetics) forged an exclusive licensing agreement with China’s RemeGen to develop and commercialize disitamab vedotin, a novel HER2-targeted antibody drug conjugate (ADC).

Biogen

Biogen’s quest to develop additional medicines for Alzheimer’s disease beyond the company’s newly approved aducanumab hit a clinical snag as the anti-tau antibody gosuranemab failed to meet endpoints in a Phase II study and was discontinued.

Shanghai, China-based SciNeuro Pharmaceuticals and U.S.-based Eli Lilly inked an exclusive license deal to develop and commercialize alpha-synuclein targeted antibody treatments in Greater China

ARC Therapeutics launched with a $6 million financing led by founding investor Eshelman Ventures LLC.

Business updates for various pharma and life science companies around the globe.